非酒精性脂肪性肝病中肝脂肪变性的非侵入性血清生物标志物：现状与未来发展。
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
机构信息
Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2023 Feb;29(Suppl):S150-S156. doi: 10.3350/cmh.2022.0362. Epub 2023 Jan 25.
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progression of NASH and fibrosis. In addition, more convenient and easily diagnosable serum biomarkers are becoming crucial in disease diagnosis. In this report, we summarize the known serum biomarkers for liver steatosis and provide guidance for their application in clinical practice.
摘要
非酒精性脂肪性肝病（NAFLD）影响着全球约 30%的人口，包括非酒精性脂肪肝、非酒精性脂肪性肝炎（NASH）和肝硬化。由于与 NAFLD 相关的疾病始于脂肪变性，因此早期诊断脂肪变性有助于阻止 NASH 和纤维化的进展。此外，更方便和易于诊断的血清生物标志物在疾病诊断中变得至关重要。在本报告中，我们总结了已知的用于诊断肝脂肪变性的血清生物标志物，并为它们在临床实践中的应用提供了指导。
相似文献
1
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.非酒精性脂肪性肝病中肝脂肪变性的非侵入性血清生物标志物：现状与未来发展。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S150-S156. doi: 10.3350/cmh.2022.0362. Epub 2023 Jan 25.
2
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.非酒精性脂肪性肝病的无创评估：当前证据与实践
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307.
3
Liver fibrosis markers of nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的肝纤维化标志物
World J Gastroenterol. 2015 Jun 28;21(24):7427-35. doi: 10.3748/wjg.v21.i24.7427.
4
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝脏疾病的无创评估。
Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18.
5
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的进展监测和治疗终点评估。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S228-S243. doi: 10.3350/cmh.2022.0401. Epub 2022 Dec 14.
6
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的诊断和评估，包括无创生物标志物和瞬时弹性成像。
Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.
7
Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.血清生物标志物和联合诊断标志物在非酒精性脂肪性肝病中的研究进展。
Dis Markers. 2022 Jun 29;2022:1254014. doi: 10.1155/2022/1254014. eCollection 2022.
8
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?非酒精性脂肪性肝病的无创诊断：我们做到了吗？
Metabolism. 2016 Aug;65(8):1087-95. doi: 10.1016/j.metabol.2016.01.013. Epub 2016 Feb 2.
9
Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 的检测现状。
Cells. 2019 Aug 7;8(8):845. doi: 10.3390/cells8080845.
10
Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.血清细胞角蛋白-18及其与非酒精性脂肪性肝病和丙型肝炎病毒患者通过FibroScan诊断的肝纤维化及受控衰减参数测定的肝脂肪变性的关系。
Eur J Gastroenterol Hepatol. 2019 May;31(5):633-641. doi: 10.1097/MEG.0000000000001385.
引用本文的文献
1
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis.基于身体成分分析的代谢功能障碍相关脂肪性肝病肝脂肪变性定量分析
Sci Rep. 2025 Aug 30;15(1):31982. doi: 10.1038/s41598-025-17396-1.
2
Metabolic and hepatic biomarkers associated with MASLD in the Chinese population.中国人群中与代谢相关脂肪性肝病（MASLD）相关的代谢和肝脏生物标志物。
Sci Rep. 2025 Aug 27;15(1):31593. doi: 10.1038/s41598-025-17219-3.
3
MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality.MOFI-FL，一种用于检测肝脂肪变性和预测心脏代谢性死亡率的新型评分系统。
Sci Rep. 2025 Aug 19;15(1):30363. doi: 10.1038/s41598-025-15487-7.
4
L-Phenylalanine promotes liver steatosis by inhibiting BNIP3-mediated mitophagy.L-苯丙氨酸通过抑制BNIP3介导的线粒体自噬促进肝脏脂肪变性。
Mol Med. 2025 Jun 30;31(1):250. doi: 10.1186/s10020-025-01303-5.
5
Associations Between Shift Work, Sociodemographic and Lifestyle Characteristics, Body Measurements, and MASLD.轮班工作、社会人口学和生活方式特征、身体测量指标与代谢功能障碍相关脂肪性肝病之间的关联。
Life (Basel). 2025 Jun 16;15(6):961. doi: 10.3390/life15060961.
6
Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.代谢功能障碍相关脂肪性肝病（MASLD）的管理——来自印度糖尿病专家视角的专家共识声明
Diabetes Obes Metab. 2025 Jun;27 Suppl 4(Suppl 4):3-20. doi: 10.1111/dom.16496. Epub 2025 Jun 2.
7
Development and Validation of a Risk Prediction Model Based on Inflammatory and Nutritional Composite Indicators for Posthepatectomy Liver Failure Following Radical Resection of Hepatocellular Carcinoma.基于炎症和营养复合指标的肝细胞癌根治性切除术后肝切除术后肝功能衰竭风险预测模型的开发与验证
J Inflamm Res. 2025 Apr 18;18:5261-5279. doi: 10.2147/JIR.S515918. eCollection 2025.
8
Construction and evaluation of a diagnostic model for metabolic dysfunction-associated steatotic liver disease based on advanced glycation end products and their receptors.基于晚期糖基化终末产物及其受体构建和评估代谢功能障碍相关脂肪性肝病的诊断模型
Front Med (Lausanne). 2025 Mar 28;12:1539708. doi: 10.3389/fmed.2025.1539708. eCollection 2025.
9
Atherogenic index of plasma identifies subjects with severe liver steatosis.血浆致动脉粥样硬化指数可识别出患有严重肝脂肪变性的受试者。
Sci Rep. 2025 Mar 17;15(1):9136. doi: 10.1038/s41598-025-93141-y.
10
Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults.用于鉴别年轻成人代谢功能障碍相关脂肪性肝病的非侵入性指标的性能
Gut Liver. 2025 Jan 15;19(1):116-125. doi: 10.5009/gnl240323. Epub 2024 Dec 6.
本文引用的文献
1
A Reappraisal of the Diagnostic Performance of B-Mode Ultrasonography for Mild Liver Steatosis.B 型超声对轻度肝脂肪变诊断性能的再评价。
Am J Gastroenterol. 2023 May 1;118(5):840-847. doi: 10.14309/ajg.0000000000002020. Epub 2022 Sep 21.
2
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach.采用分层贝叶斯方法预测 2040 年非酒精性脂肪性肝病的全球患病率。
Clin Mol Hepatol. 2022 Oct;28(4):841-850. doi: 10.3350/cmh.2022.0239. Epub 2022 Sep 19.
3
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults.代谢评分对胰岛素抵抗预测韩国成年人非酒精性脂肪性肝病发病的作用。
Clin Mol Hepatol. 2022 Oct;28(4):814-826. doi: 10.3350/cmh.2022.0099. Epub 2022 Jun 9.
4
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南：非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
5
Recent advances in nonalcoholic fatty liver disease metabolomics.非酒精性脂肪性肝病代谢组学的最新进展。
Clin Mol Hepatol. 2021 Oct;27(4):553-559. doi: 10.3350/cmh.2021.0127. Epub 2021 Jun 8.
6
Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance.一种简单的非酒精性脂肪性肝病评分系统的开发，该系统可指示代谢风险和胰岛素抵抗。
Ann Transl Med. 2020 Nov;8(21):1414. doi: 10.21037/atm-20-2951.
7
Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting.社区环境中肝脂肪变性公式的比较评估与外部验证
J Clin Med. 2020 Sep 3;9(9):2851. doi: 10.3390/jcm9092851.
8
Recent research trends and updates on nonalcoholic fatty liver disease.非酒精性脂肪性肝病的最新研究趋势和进展。
Clin Mol Hepatol. 2019 Mar;25(1):1-11. doi: 10.3350/cmh.2018.0037. Epub 2018 Aug 8.
9
NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver.NAFL 筛查评分：一种可识别超声诊断的非酒精性脂肪肝的基本评分。
Clin Chim Acta. 2017 Dec;475:44-50. doi: 10.1016/j.cca.2017.09.020. Epub 2017 Sep 28.
10
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
Zotero 插件